ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum

Medical device company Zimmer Biomet (NYSE:ZBH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 10.9% year on year to $2.24 billion. Its non-GAAP profit of $2.42 per share was 0.9% above analysts’ consensus estimates.

Is now the time to buy ZBH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Zimmer Biomet’s fourth quarter results were greeted positively by the market, with management crediting strong execution in the U.S. and robust demand for recently launched products as key drivers. CEO Ivan Tornos highlighted the impact of new product adoption, especially in knee and hip implants, and the effectiveness of direct-to-patient marketing campaigns. Tornos pointed to continued gains in robotics and navigation technologies, as well as double-digit growth in the company’s cranio-maxillofacial and upper extremities segments. The quarter also benefited from capital equipment sales and higher procedure volumes, with Tornos emphasizing, “the lion’s share of the performance is better execution,” especially on recent product launches.

Looking ahead, Zimmer Biomet’s guidance for 2026 reflects management’s focus on a major transformation of its U.S. salesforce. Tornos explained this transition to a fully dedicated and specialized sales team is expected to create short-term disruption but is seen as critical for long-term growth. The company’s guidance assumes headwinds from this reorganization, as well as pricing pressure and international market uncertainties. CFO Suketu Upadhyay noted that operating margins will be pressured in the near term due to increased investments, but that cost efficiencies and new product launches should support free cash flow growth. As Tornos concluded, “It will create some short-term disruption, but it’s going to set the company very nicely as we enter 2027 and beyond.”

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to new product momentum, expanded robotic offerings, and a targeted U.S. sales approach, while also addressing the impact of organizational changes and recent acquisitions.

• New product adoption: Growth in U.S. knees and hips was fueled by increased adoption of the Persona OsteoTide cementless knee and Oxford Partial Cementless Knee, with the latter benefitting from direct-to-patient campaigns and competitive account conversions.
• Robotics and technology gains: The U.S. saw its strongest robotic capital sales quarter in over two years, with the company’s comprehensive suite of navigation and digital solutions driving double-digit growth in technology-related sales.
• Salesforce transformation underway: The shift to a fully dedicated and specialized U.S. salesforce is already one-third complete; management expects this to meaningfully improve productivity and competitiveness in high-growth areas such as robotics and ambulatory surgical centers (ASCs).
• International and segment trends: International growth was supported by new product launches and strong robotic sales, while the cranio-maxillofacial and upper extremities businesses delivered high single- to mid-teens growth, offsetting challenges in trauma and restorative therapies in the U.S.
• Integration of acquisitions: The recent Paragon 28 and Monogram deals are contributing to the portfolio, with management emphasizing ongoing integration progress and a temporary pause in further M&A to focus on execution and shareholder returns.

Drivers of Future Performance

Zimmer Biomet’s outlook is shaped by its U.S. salesforce transition, ongoing product launches, and efforts to address pricing and margin pressures.

• U.S. salesforce reorganization: The move to a dedicated, specialized sales team is expected to temporarily disrupt growth but is aimed at closing productivity gaps with peers and boosting adoption of new products. Management expects the transition to be complete by the end of 2027, with visible productivity gains anticipated as the process matures.
• Pricing and margin headwinds: Management forecasts up to 100 basis points of global pricing erosion for 2026, driven by regulatory price resets in Japan and China and continued competition in the U.S. These factors, along with ongoing investments in commercial infrastructure, are expected to pressure operating and gross margins in the near term.
• International and product pipeline: The company anticipates steady international growth, especially from recent launches like iodine-coated implants in Japan and the advancing “magnificent seven” platform. Continued investment in robotics and digital solutions is expected to drive adoption in both developed and emerging markets.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will closely monitor (1) the pace and impact of the U.S. salesforce transformation, especially in accelerating new product adoption; (2) progress on gross and operating margin stabilization as cost and pricing pressures persist; and (3) the integration and performance of recent acquisitions like Paragon 28 and Monogram. Execution on major product launches, such as the MBOS robotic system and iodine-coated implants, will also be key indicators of strategic progress.

Zimmer Biomet currently trades at $91.57, up from $89.73 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.